Add like
Add dislike
Add to saved papers

Multicenter observational cohort study of endoscopic band ligation without resection of small-sized subepithelial tumours of the digestive tract (Banding-SET): a clinical protocol.

BACKGROUND AND AIMS: Endoscopic band ligation (EBL) without resection combined with a single-incision needle-knife (SINK) biopsy may have a positive impact on small gastrointestinal subepithelial tumor (SET) management, but it needs to be tested. The aim was to evaluate the feasibility of this strategy in small-sized SET.

METHODS: This prospective multicenter observational cohort study in 7 centers included patients with SETs ≤15mm (confirmed by endoscopic ultrasound (EUS)) between March 2017 and March 2020. The primary outcome was 4 weeks clinical success defined as complete SET disappearance at EUS control. Secondary outcomes were long-term (1 year) clinical success, technical difficulty level, clinical impact, yield pathology, and safety.

CLINICALTRIALS: gov, NCT03247231.

RESULTS: Some 273 patients were screened, and 122 (62.3% women, mean age 60.9±13.2) were included with SET (mean size, 9mm±2.8; gastric location 77%, superficial layer-dependence 63%). Primary endpoint was achieved in 73.6% (95%CI 64.8-81.2). At 1-year follow-up, success rate was 68.4% (95%CI 59.1-76.8). A favorable clinical impact was observed in 97 cases (79.5%, 95%CI 71.3-86.3). Pathology diagnosis was known in 70%. Potentially malignant lesions were present in 24.7%. Related-adverse events rate was 4.1% (95%CI 1.3-9.3; all mild, n=2 bleeding, n=2 abdominal pain). On multivariable analysis, ≤10mm SET group was associated with a greater success rate (1-year, 87%; RR5.07[95%CI 2.63 - 9.8]) and clinical impact rate (92.7%; RR6.15 [95%CI 2.72 - 13.93].

CONCLUSIONS: EBL plus SINK-biopsy seems to be feasible, and safe, and it may offer a favorable clinical impact in small-sized SETs. Concretely, SETs ≤10mm are the best candidates.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app